242 filings
Page 8 of 13
CORRESP
dqt78y3cj xz
23 Apr 19
Correspondence with SEC
12:00am
UPLOAD
s8tw3
19 Apr 19
Letter from SEC
12:00am
8-K
qd6m3ynx42i4fqs
25 Feb 19
CRISPR Therapeutics and Vertex Announce Progress in Clinical Development Programs for the Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001
8:16am
8-K
toqs5nrmwn693f5
25 Feb 19
CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2018 Financial Results
8:15am
CT ORDER
4z2902csfmp9k3cet1b
30 Nov 18
Confidential treatment order
11:08am
8-K
piyx ei08u
9 Nov 18
Other Events
12:00am
424B5
nynw0i
9 Nov 18
Prospectus supplement for primary offering
12:00am
8-K
l2cjnjhg8 r46ihlmy
7 Nov 18
CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2018 Financial Results
5:22pm
8-K
0eatv16
10 Oct 18
Regulation FD Disclosure
5:25pm
424B5
f39j9cnwk5lxcab4t
24 Sep 18
Prospectus supplement for primary offering
8:23pm
8-K
ad0o6
24 Sep 18
Entry into a Material Definitive Agreement
5:27pm
8-K
hl83g
21 Sep 18
Crispr Therapeutics Announces Proposed Public Offering of Common Shares
4:16pm
424B5
sn40q yjz9xd4alwx3
21 Sep 18
Prospectus supplement for primary offering
4:10pm
424B5
pvz9d50h4cg254
19 Sep 18
Prospectus supplement for primary offering
4:21pm
S-3ASR
jsf5l9f
19 Sep 18
Automatic shelf registration
4:02pm
8-K
rxgqj 0ujku
17 Sep 18
CRISPR Therapeutics and ViaCyte Announce Strategic Collaboration to Develop Gene-Edited Stem Cell-Derived Therapy for Diabetes
12:00am
8-K
4w9jer7qrjl3y n7vbng
11 Sep 18
Other Events
12:00am